Serum Copeptin Rises After Tolvaptan for Hyponatraemia, but Does Not Predict Risk of Rapid Sodium Rise: Pre‐Specified Secondary Analysis of the TVFR Trial

Clinical Endocrinology · Published 2026-08-03 · DOI 10.1111/cen.70184

Free full text

Authors (5)

Annabelle M. Warren, Kay Weng Choy, Rudolf Hoermann, Nicholas Russell, Mathis Grossmann

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Warren, A., Choy, K., Hoermann, R., et al. (2026). Serum Copeptin Rises After Tolvaptan for Hyponatraemia, but Does Not Predict Risk of Rapid Sodium Rise: Pre‐Specified Secondary Analysis of the TVFR Trial. Clinical Endocrinology. https://doi.org/10.1111/cen.70184

Related articles